Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News AgeneBio enrolls first patient in phase 3 trial for AGB101 in MCI due to Alzheimer’s Disease AgeneBio, a leading biopharmaceutical company specialising in central nervous system (CNS) disorders, has announced the enrolment of the… bypharmanewsdailyJanuary 30, 2019